-
POSTER
Pharmacokinetic (PK), Safety, and Efficacy Data on Cohort IIA; Youth Aged 6 to
11 Years
from IMPAACT P1066: A Phase I/II Study to Evaluate Raltegravir (RAL) in HIV-1
Infected Youth
S Nachman, P Samson, E
Acosta, et al
(17 CROI)
PDF Poster
Abstract
-
Interim
Results from IMPAACT P1066: Raltegravir (RAL) Oral Chewable Tablet (OCT)
Formulation
in Children 6 to 11 Years
S Nachman, E Acosta, P
Samson, et al
(17 CROI)
Abtract
-
POSTER
Raltegravir In Children and Adolescents: The French Expanded Access Program
I Thuret, C Tamalet, V
Reliquet, et al
(16th CROI)
PDF Poster
Abstract
-
POSTER
Safety and Efficacy of Raltegravir in Pediatric HIV Infection. Preliminary
Analysis from
the International Maternal
Pediatric Adolescent AIDS Clinical Trials Group, P1066
A Wiznia, P Samson, E
Acosta, et al
(16th CROI)
PDF
Poster
Abstract
|
|
New
and Noteworthy
Database
of ARV Drug Interactions
Main
New/Newsworthy
